Welcome
Support Centre
24 May 2013 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   news
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes
statistics

[ Print-friendly version ]
Evaluation of a new technology to treat urinary incontinence in women
ISRCTN ISRCTN74508432
DOI 10.1186/ISRCTN74508432
ClinicalTrials.gov identifier
EudraCT number
Public title Evaluation of a new technology to treat urinary incontinence in women
Scientific title Evaluation of a new technology to treat urinary incontinence in women: a single blind randomised controlled trial
Acronym FEMESTIM
Serial number at source FEMESTIM CIP 002
Study hypothesis Null hypothesis: There will be no difference in outcome for women with urinary stress incontinence between those receiving standard written information about pelvic floor muscle exercises and those receiving this written information plus a novel electrical stimulation device (FEMESTIM) for restoring pelvic floor function.
Lay summary Lay summary under review 1
Ethics approval North Sheffield Ethics Committee approved in January 2009, reference number 06/Q2308/134
Study design Single blind randomised controlled trial
Countries of recruitment United Kingdom
Disease/condition/study domain Urinary incontinence
Participants - inclusion criteria All women:
1. Who suffer from stress incontinence
2. Who self refer
3. Who are interested in participating in the study
Participants - exclusion criteria 1. Age under 18 years or more than 65years
2. Lack of consent to stimulation
3. Pregnancy
4. Implanted pacemaker
5. Recent pelvic surgery (within last 3 months)
6. Recent haemmorhage / haematoma / tissue damage
7. Previous or at presently undergoing any active therapy for pelvic malignancy
8. Urinary tract infection
9. Vaginal infection
10. Atrophic vaginitis
11. Diabetes or neurological condition
12. Any lesions or other pathology of the vagina or labia
13. Manual dexterity insufficient to place the device
14. Previously had treatment for their urinary incontinence
15. Refusal to provide permission for general practitioner (GP) examination
16. GP determination that the patient is not suitable for participation in the investigation
17. Had baby within the previous 3 months
Anticipated start date 01/05/2009
Anticipated end date 31/12/2011
Status of trial Completed
Patient information material Not available in web format, please use the contact details below to request a patient information sheet
Target number of participants 200
Interventions All women are supplied with the same magazine article outlining current self help treatment for urinary incontinence.

The women in the novel stimulation device group are supplied with enough single use disposable electrodes to last them for twelve weeks of stimulation. Devices will be used for 30mins per day on a daily basis and switch on automatically on insertion into the vagina and switch off automatically after the 30mins time period after which time they are removed and discarded. Women in this group also receive an instruction leaflet regarding pelvic floor muscle exercises that should be undertaken during the course of the study.
Primary outcome measure(s) Quality of life measured at week 2, weeek 4 and week 12 through completion of the short form version of the International Consultation on Incontinence Questionnaire (ICIQ-UI)
Secondary outcome measure(s) 1. Patient Global Impression of Severity and of Improvement
2. Sexual dysfunction questionnaire (ICIQ-FLUTSex)
3. Diary of stimulation use and compliance
Measured at week 2, weeek 4 and week 12
Sources of funding Femeda Ltd (UK)
Trial website
Publications
Contact name Prof  Jackie  Oldham
  Address Centre for Rehabilitation Science
University of Manchester
Manchester Interdisciplinary Biocentre
131 Princess Street
  City/town Manchester
  Zip/Postcode M1 7DN
  Country United Kingdom
  Email jackie.oldham@manchester.ac.uk
Sponsor Femeda Ltd (UK)
  Address Westminster Business Centre
Lion Court
Hanzard Drive
Wynyard Business Park
  City/town Wynyard
  Zip/Postcode TS22 5FD
  Country United Kingdom
  Sponsor website: http://www.femeda.com
Date applied 10/08/2011
Last edited 20/08/2012
Date ISRCTN assigned 20/09/2011
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2013 ISRCTN unless otherwise stated.